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1. Introduction
Worldwide, more than 1 million people develop colorectal cancer (CRC) annually [1]. CRC
is a major health problem in the Western world and the second most common cause of
cancer  mortality  [2].  To  improve  performance,  the  role  of  chemotherapy  for  CRC  has
increased dramatically over the last decade. Of course surgery remains the cornerstone of
treatment,  the  vast  majority  of  CRC  patients  now  receive  chemotherapy  with  multiple
agents that are currently approved for the treatment in the appropriate setting. However,
it  is a complex process to select the optimal chemotherapy for each patient and practice
evidence gap is still a problem. We found large differences in patterns of institution, region
and country.  The results  suggest  that  the lack of  evidence for CRC chemotherapy prac‐
tice still exists around the world. [3] Recently, standardization of cancer treatment, including
chemotherapy, has become of particular importance for the quality of cancer therapy. It is
important  to  know whether  the overhaul  performed normalization of  CRC chemothera‐
py. Measures and quality indicators are needed and several studies on indicators of quality
of  cancer  care  have  been reported.  However,  measures  to  assess  the  standardization of
cancer therapy are not well established. In this study, we evaluated the usefulness of the
oncology market research to assess the evidence gap in practice CRC chemotherapy. We
also discuss the role of the method to measure the effect of normalization of CRC chemo‐
therapy. [4, 5]
Although  surgery  remains  the  cornerstone  of  treatment,  the  vast  majority  of  CRC  pa‐
tients  now receive  chemotherapy to  reduce the  risk  of  metastatic  spread by eradicating
microscopic  tumor  foci  that  are  distant  from  the  primary  tumor  and  undetectable  in
© 2014 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
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perioperative assessment of tumor extension. [5] Five-year survival of patients are mainly
determined  by  the  histological  stage  of  the  tumor  at  the  time  of  resection.  The  most
important prognostic factor for survival in patients without visceral metastases is the stage
of the tumor determined by the depth of penetration of the tumor in the bowel wall and
the number of lymph nodes [4] (lymph nodes >12 examined). Result of the meta - analy‐
sis  of  over  10  studies  showed  that  each  -  two-month  delay  of  adjuvant  chemotherapy
resulted  in  a  14%  decrease  in  overall  survival,  suggesting  that  adjuvant  chemotherapy
should be administered as soon as possible [5].
The introduction of new cytotoxic agents such as oral fluoropyrimidines, oxaliplatin and
irinotecan in chemotherapy (CT) regimens have improved the response rate, disease-free
survival (DFS) and overall survival (OS) in patients with metastatic colorectal cancer. [6, 7]
This has encouraged the trials in the adjuvant treatment of non-metastatic disease, especially
in patients with stage III tumors. Table 1 shows the most common regimens used for the
CT adjuvant. Surgery alone is usually curative for colon cancer stage II, but about 20% to
30% of  these  patients  develop recurrence  and die  of  metastatic  disease.  [8]  This  under‐
pins  the  need  for  prognostic  factors  such  as  microsatellite  instability  (MSI),  which  are
potentially  predictive  of  tumor  response  to  cytotoxic  agents.  [7]  Prognostic  factors  are
particularly useful in the context of stage II colorectal cancer, where the benefits of cytotoxic
adjuvant  therapy  are  more  controversial  than  in  stage  III  disease.  The  identification  of
accurate  and  validated  predictive  and  prognostic  markers  help  clinicians  in  choosing
appropriate use of adjuvant chemotherapy in patients with stage II CRC.
MSI is  a  change in the length of  microsatellite  DNA due to the insertion or deletion of
repeating units  –  from 1to 5 nucleotides caused by defects  in mismatch repair  genes or
methylation  of  their  promoters.  [9]  Tumors  with  MSI  are  more  often  proximal,  poorly
differentiated, mucinous, and show a significant lymphocytic infiltration. [9] Colon cancers
with high-frequency MSI have clinical and pathological features that distinguish them from
microsatellite stable tumors and MSI is a marker of favorable outcome and a predictor for
the benefit  decreased from fluorouracil  -  based adjuvant  chemotherapy in patients  with
stage II  or  colon cancer  stage III  with  microsatellite  stable  tumors  or  tumors  with low-
frequency  microsatellite  instability.  [10]  Silence  or  mutation  of  mismatch  repair  (MMR)
genes can lead to protein deficiency MMR and MSI 10. This is observed in patients with
Lynch syndrome, and it is a rare cause of hereditary colon cancer 2 to 4% of the 11 cases.
Somatic mutation is reported in 19% of CRC [12], while silencing of MMR genes can be
observed in up to 52% of sporadic colon cancers [13].
In sporadic CRC, three tumor phenotypes were defined: microsatellite stable (MSS), low-
frequency MSI (MSI-L) and high frequency MSI (MSI-H). It has been reported that MSI-H are
more frequently found in stage II disease than in stage III disease 14. This may partly explain
the benefit decreased from 5 - fluorouracil adjuvant chemotherapy (5FU) in patients with stage
II. Tente identify patients who might benefit from adjuvant chemotherapy led to the devel‐
opment of multigene tests as several Oncotype DX etc. Unfortunately, there is no evidence that
any of them can predict the potential benefit of adjuvant chemotherapy. [13]
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2. Treatment guidelines for CRC
Some guidelines for the treatment of CRC have been developed to promote the standardization
of CRC treatment. Only two drugs, panitumumab and cetuximab first line were still causing
discord. Bevacizumab or capecitabine combined with oxaliplatin is used for the treatment of
advanced and recurrent CRC, while the FOLFOX regimen is used in patients with a high risk
of recurrence in the adjuvant chemotherapy. In this major revision, current controversies are
treated as clinical issues with many references.
Adjuvant  5-FU  chemotherapy  is  the  standard  treatment  used  in  patients  with  stage  III
(Dukes C) and high-risk stage II (Dukes B) tumors. Capecitabine and bolus 5FU regimes
have proven efficacy and are associated with a low risk of severe toxicity. The addition of
oxaliplatin to 5FU improves patient outcomes in the adjuvant setting. Mosaic of random‐
ized trials in 2246 patients with stage 2 or 3 of the CRC to receive LV5FU2 or FOLFOX-4
chemotherapy. The operating system after 6 years of follow-up for all patients was 78.5%
for FOLFOX-4 against 76% for LV5FU2. Subgroup analysis showed stage-specific 6-year OS
rate of 72.9% against 68.7% in patients with stage 3 of the CRC and 86.9% compared with
86.8% in patients with stage 2 CRC for FOLFOX-4 and LV5FU2, respectively. The NSABP
C-07 trial  had a similar design, the addition of oxaliplatin to 5FU adjuvant chemothera‐
py, but used a different calendar 5FU and oxaliplatin doses delivered also less than in the
MOSAIC study (nine against twelve). The first results showed a similar improvement in
disease-free survival (DFS) than that observed in the MOSAIC trial. A recently presented
the  final  results  confirm  improved  DFS,  but  showed  shorter  survival  time  after  recur‐
rence in the oxaliplatin arm and an improvement in overall survival has not been seen. A
significant  interaction  between  age  and  survival  of  certain  parameters  were  observed.
Patients less than 70 years appeared to benefit from the addition of oxaliplatin while patients
over 70 years,  no benefit  was observed consistently.  The analysis  of  the ACCENT data‐
base, including 10, 449 patients less than 70 years and 2170 patients over 70 years from six
randomized trials have demonstrated a significant interaction between age and treatment
effect. No differences in results were noted between experimental (combination) chemother‐
apy and chemotherapy in patients with fluoropyrimidine control  over 70 years.  Adding
oxaliplatin to 5FU increases the overall incidence of grade 3 toxicity and is associated with
the occurrence of peripheral sensory neuropathy. Over 90% of patients experience tempora‐
ry  symptoms typically  induced cold,  with  a  minority  of  patients  with  persistent  symp‐
toms affecting activities of daily living (grade 2 and 3 toxicity). In the MOSAIC study, grade
3 peripheral sensory neuropathy was noted in 12.5% of patients treated with oxaliplatin for
the treatment. After 48 months of follow-up, rates of toxicity were grade 11.9% 1, % [22] 8
degree and 0.7% grade 3, respectively. Similar data were presented for the NSABP C-07
study.
Decisions regarding the use of  adjuvant  chemotherapy combinations are  more complex.
The incidence of approximately 3% of significant long-term peripheral neuropathy and MS
MT  Seymour  Braun  could  interfere  with  the  activities  of  the  daily  life  of  the  patient
influences decision-making in relation to the small additional benefit accrued to receive the
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oxaliplatin.  MOSAIC  and  NSABP  the  C-07  trials  delivered  a  total  dose  of  oxaliplatin
different, but both studies noted similar improvements in DFS. International trials evaluat‐
ing shorter periods of oxaliplatin-based chemotherapy in the adjuvant setting (12 versus 24
weeks  of  chemotherapy  oxaliplatin/5FU  ISRCTN  59757862)  in  order  to  assess  the  non-
inferiority of short periods of treatment, as well as consideration of the evaluation criteria
of quality of life. The relative benefit of chemotherapy is also a key factor in the choice of
treatment for patients in the adjuvant setting.  Patients with stage 3 are a heterogeneous
group and decisions based on age, the relative risk of recurrence (N1 N2 against disease),
and the additional benefit that can be achieved by adding oxaliplatin need to be carefully
considered. Given the new data in patients over 70 years, it seems likely that chemothera‐
py oxaliplatin are used less frequently in this group. Patients with disease stage 2 have an
excellent  prognosis  with  or  without  chemotherapy  5FU-based  and  high-risk  patients
functions are selected for processing. Both C-07 and MOSAIC are powered to assess the
benefit of adding oxaliplatin to 5-FU in patients with stage 2 disease, but a trend towards
improved DFS was noted. However, no OS benefit is probably very low in absolute terms
(<2%) and difficult to justify given the excellent overall performance (> 80% at 5 years of
operation) and the risk of neurotoxicity. [23]
3. 5FU
In  1990,  Moertel  and  colleagues  first  reported  the  value  of  adjuvant  chemotherapy  in
patients  with  stage  III  colon cancer  (Dukes  C,  Tx  N +  M0).  [15]  This  study showed an
increase  in  overall  survival  and  progression-free  survival  in  patients  receiving  5FU/
Levamisole - based chemotherapy for 1 year against levamisole alone or without chemother‐
apy. With a median follow - up of 6.5 years, patients treated with 5-FU / levamisole showed
a 40% reduction in recidivism and an estimated reduction of 33% of overall mortality [16].
5-FU is a pyrimidine analogue, which inhibits thymidylate synthase (TS) (involved in the
de novo synthesis of thymidine) and is involved in incorporation into RNA and DNA with
the  inhibition  of  DNA synthesis  and function  [17].  With  5FU bolus  injection  maximum
concentration is reached in the plasma and bone marrow 100-1000 times higher than with
continuous infusion. More than 85% of the administered drug is inactivated by dihydropyr‐
imidine dehydrogenase (DPD), expressed mainly in the liver.  Some mutation in DPD in
about  2%  in  the  general  population  can  lead  to  serious  life-threatening  toxicity  [17].
Leucovorin (LV) or folinic acid enhance the antitumor activity of 5FU. Today, there is a
lack  of  LV  in  the  United  States,  despite  the  absence  of  specific  data  confirming  this
statement. The QUASAR study investigators demonstrated that patients treated with 175
mg of LV similar survival and 3 - year recurrence rate of LV 25 mg when administered as
a  bolus  5-FU as  adjuvant  therapy for  CRC 7.  Similar  results  have been reported in  the
parameters in metastatic CRC patients -  there was no difference in survival or response
rate in patients receiving 5FU bolus high - dose or low-dose LV [18]. Therefore, when LV
is not available without LV treatment is reasonable. Comparison of monthly bolus FU / LV
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regimen (5FU bolus followed by LV 15 minutes) with double - monthly infusion LV5FU2
(LV for 2 hours, followed by bolus 5-FU, followed by a continuous infusion of 5-FU over
2 days) in 905 patients with stage II (43%) or III (57%) colon cancer showed that the regime
was less toxic LV5FU2, especially regarding hematological and gastrointestinal events (P
<0.001) [19]. No significant difference in DFS and OS was observed in one of two regi mens
median follow-up 6 years. Two other studies have shown that the two ways of 5FU bolus
administration combined with LV with or without levamisole and a continuous infusion of
5-FU  are  equivalent.  Saini  and  colleagues  conducted  a  multicenter  randomized  trial
comparing the efficacy and toxicity of 12 weeks of 5FU delivered by continuous intrave‐
nous  infusion against  the  standard bolus  5-FU and LV for  6  months  as  adjuvant  treat‐
ment in colorectal cancer. The two schemes are equivalent, but the plan 12 weeks was less
toxic [20]. The analysis of data from several trials in which patients were randomly resection
of the tumor or tumor resection followed by adjuvant 5-FU/LV showed that the benefit of
adjuvant chemotherapy was observed in patients with stage III [21, 22], which suggests that
because of nodal status of these patients are at higher risk. Both studies showed that the
addition  of  oxaliplatin  to  5-FU/LV as  adjuvant  therapy  in  stage  II  and  elderly  patients
showed no significant DFS or OS [23, 24] benefits even in patients with characteristics high
risk - T4 tumors, intestinal obstruction, venous invasion, etc. This suggests that, despite the
failure  of  our  definition  of  high-risk  patients  with  stage  II,  5-FU/LV  regimen  may  be
preferable. QUASAR investigators reported their analysis of 3238 patients, the majority of
them  were  in  stage  II  colon  cancer.  Patients  were  randomized  to  receive  5-FU/LV  or
observation. The relative risk of death from all causes in the 5-FU/LV arm versus observa‐
tion was 0.82 (95% CI, 0.70 to 0.95, p = 0.008). The relative risk of recurrence was 0.78 (95%
CI, 0.67-0,  91,  p = 0.001) [7].  The investigators did not separate patients into individuals
high or low risk. Risk factors are obstruction or bowel perforation, elevated preoperative
CEA,  poorly  differentiated tumors,  removal  of  CDC patients  and MSI-S.  The  impact  of
adjuvant chemotherapy and the potential benefit of this new could not be clearly demon‐
strated in this study of patients with stage II.
4. Oral fluoropyrimidines
Two oral  prodrugs of  5FU -  capecetabine and uracil  /  tegafur  (UFT),  has  demonstrated
efficacy in metastatic disease, which is comparable with bolus 5-FU/LV regimens [25, 26].
After  oral  administration,  capecitabine  is  rapidly  absorbed  with  plasma  concentrations
peaking after 1.5 hours [27]. Pharmacokinetics is largely dose - dependent. The pharmacol‐
ogy of capecitabine is not significantly influenced by gender, race, performance status, body
surface area, albumin or hepatic dysfunction [28]. The half-life of capecitabine is between
0.49 and 0.89 hours, whereas the half-life of the metabolite (5-FU) extends from 0.67 to 1.15
hours [29]. Regarding renal excretion primarily (more than 70% of metabolites), capecita‐
bine is against - in patients with severe renal impairment (creatinine clearance less than 30
mL / min).
Adjuvant Treatment in Colorectal Cancer
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Therapy Mechanism of Action Indications Potential Common Toxicities
5- Fluorouracil (5FU) Blocks the enzyme
thymidylate synthase (TS),
which is essential for DNA
synthesis
Multiple uses in
combination with other
agents, both in the
adjuvant (postop) and
palliative setting
Gastrointestinal (nausea,
diarrhea)
Myelosuppression
Fatigue
Capecitabine Blocks thymidylate synthase
(orally administered prodrug
converted to 5FU)
Multiple uses in
combination with other
agents, both in the
adjuvant (postop) and
metastatic setting
Gastrointestinal (nausea,
diarrhea)
Myelosuppression
Fatigue
Palmar-plantar syndrome
(hand-foot syndrome)
Oxaliplatin Inhibits DNA replication and
transcription by forming
inter- and intra-strand DNA
adducts/cross-links
Used in combination with
5FU, leucovorin (LV)
(FOLFOX) in the adjuvant
(postop) and metastatic
setting
Peripheral neuropathy
Gastrointestinal (nausea,
diarrhea)
Fatigue
Myelosuppression
Hypersensitivity
Irinotecan Inhibits topoisomerase I, an
enzyme that facilitates the
uncoiling and recoiling of
DNA during replication
Used alone or in
combination with 5FU, LV
(FOLFIRI) in the metastatic
setting
Cholinergic (acute diarrhea)
Gastrointestinal (nausea,
late diarrhea)
Fatigue
Myelosuppression
Alopecia
Bevacizumab Monoclonal antibody which
binds to VEGF ligand
Used in combination with
either FOLFOX or FOLFIRI in
the metastatic setting
Hypertension
Arterial thrombotic events
Impaired wound healing
Gastrointestinal perforation
Cetuximab Monoclonal antibody to
EGFR (chimeric) that blocks
the ligand-binding site
Used with irinotecan or as a
single agent in the
metastatic setting
Acneform rash
Hypersensitivity
Hypomagnesemia
Fatigue
Panitumumab Monoclonal antibody to
EGFR (fully humanized) that
blocks the ligand-binding
site
Used as a single agent in
the metastatic setting
Acneform rash
Hypomagnesemia
Fatigue
VEGF, vascular endothelial growth factor; EGFR, epidermal growth factor receptor.
Table 1. Types of therapeutical agents and their mechanism of action
The X-ACT (Xeloda (capecitabine) in adjuvant therapy of colon cancer) Phase III trial in
patients (N = 1.987) compared capecitabine (2500 mg / m 2 / day, 14 to 21 days) for bolus 5-FU/
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LV. After a median follow-up of 6.9 years, both treatments showed similar efficacy in terms
of DFS and OS [30]. The HR for DFS of capecitabine compared 5-FU/LV was 0.88 (95% CI, 0.77
to 1.01), the upper limit of the 95% is well below the predefined non-inferiority margin of 1.20
(p <0.0001) [30]. The 5-year DFS rate for capecitabine and 5-FU/LV were 60.8% and 56.7%,
respectively. These monitoring data confirm that, as adjunctive therapy for patients with colon
cancer resected stage III oral capecitabine is at least equivalent to iv bolus treatment of 5-
FU/LV in terms of 5 - year DFS, the primary endpoint of X-ACT study. Infusional 5-FU
regimens are now often favored because they offer similar efficacy or improved slightly bolus
5-FU/LV regimes and are generally better tolerated [31]. However, the plasma concentration
profile of capecitabine is administered twice daily for 14 days, closer to that of a continuous
infusion of 5-FU bolus injections as daily or weekly 5FU.La capecitabine Profile improved
safety compared to bolus 5-FU/LV in terms of significantly lower rates of diarrhea, stomatitis,
neutropenia, nausea, alopecia, febrile neutropenia [30].
UFT and oral LV was evaluated in the adjuvant setting in the NSABP C-06 trial. More than
1000 patients with colon cancer were randomized to receive either oral or intravenous UFT
with LV 5FU with LV. 47% of patients had colon cancer stage II, and 53% had colon cancer
stage III. Median follow-up was 62.3 months time. There was no significant difference in
disease-free survival - or overall showing that the UFT is an acceptable alternative to parenteral
5-FU/LV [32]. No difference in toxicity profiles of the two regimens has been reported.
5. Adjuvant therapy combination
The hypothesis  that  the antitumor activity of  the combination agent,  including oxalipla‐
tin, irinotecan, bevacizumab, cetuximab in metastatic cure rates would result in increased
adjuvant  proved  to  be  often  wrong.  Oxaliplatin  is  a  platinum  compound  and  third
generation of the safe administration of evidence of clinical activity has been reported 33.
Platinum compounds exert their effect through the development of covalent adducts with
cellular DNA, which is not portable - specific cycle [34]. Platinum derivative oxaliplatin is
described as having a "tri-exponential" reason for removing the half - life being successive‐
ly 0.28 hours, 16.3 hours and 273 hours [35]. The fact that the third half-life of oxaliplatin
hundreds of hours, the accumulation of the drug in the tissues can reasonably be expect‐
ed. In this regard, one study examined the long - term retention of platinum 8-75 months
after treatment with cisplatin and oxaliplatin [36].  Narrow therapeutic index of oxalipla‐
tin  and  adverse  reactions  are  mainly  reported  in  the  hematopoietic  system,  peripheral
nerves, and gastrointestinal tract [35]. The addition of oxaliplatin to 5FU improves patient
outcomes in the adjuvant setting. Mosaic of randomized 2246 patients with stage II or III
CRC will LV5FU2 or FOLFOX-4 (which is LV5FU2 chemotherapy plus oxaliplatin on day
1].  The 5-year  DFS rate  of  Phase II  and III  patients  were 73.3% and 67.4% in the FOL‐
FOX-4  groups  and  LV5FU2,  respectively  (RR  0.80,  95%  CI,  0.68-0,  93,  p  =  0.003)  [37].
Subgroup analysis showed stage - specific 6 years OS rate of 72.9% against 68.7% in patients
with stage III  CRC (HR 0.80,  95% CI,  0.65-0,  97,  P  =  0.023)  and 85.0% against  83.3% in
patients with stage II CRC (P = 0.65] in the FOLFOX-4 and LV5FU2, respectively [38]. As
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expected,  the  toxicity  of  the  regimen  FOLFOX-4  was  higher  than  that  observed  in  the
LV5FU2 arm.  All  -  cause mortality  in  the  first  60  days was the same in  both arms.The
NSABP  C-07  trial  had  a  similar  design,  the  addition  of  oxaliplatin  to  5-FU  adjuvant
chemotherapy,  but  using  a  different  calendar  5FU  and  also  provide  fewer  doses  of
oxaliplatin in  the MOSAIC study (nine against  twelve).  FLOX regimen in this  trial  was
studied - oxaliplatin was given on weeks 1, 3, and 5 more per week 5-FU/LV bolus of 1-6
weeks, repeated at 8 week cycle, depending on the standard weekly 5-FU/LV treatment.
Over  2000  patients  were  randomized to  receive  5-FU/LV and FLOX treatment.  Stage  II
patients were 29% and stage III patients was 71%. The median duration of follow up was
34 months. The hazard ratio of FLOX against 5-FU/LV was 0.79 (95% CI, 0.67 to 0.93], with
a risk reduction of 21% in favor of FLOX [39]. As expected, treatment toxicity FLOX was
higher than that observed in the 5-FU/LV arm. 15 deaths were recorded in the treatment
with FLOX and 14 deaths 5-FU/LV. Update this study showed that the benefit of FLOX in
DFS was observed in 7 - year median follow - but there was no significant difference in
overall survival when the two arms were compared 24 (HR, 0.88, 95% CI, 0.74 to 1.05, P =
0.1428).  A  significant  interaction  between  age  and  survival  of  certain  parameters  were
observed. Patients less than 70 years appeared to benefit from the addition of oxaliplatin
while in patients over 70 years, no benefit was observed consistently. MOSAIC and NSABP
the C-07 trials delivered a total dose of oxaliplatin different, but both studies noted similar
improvements in DFS. International trials evaluating shorter periods of oxaliplatin - based
chemotherapy in the adjuvant setting (12 versus 24 weeks of chemotherapy oxaliplatin/5FU
ISRCTN 59757862)  in  order  to  assess  the non-inferiority  of  short  periods treatment.Both
NSABP C-07 and MOSAIC are powered to assess the benefit  of adding oxaliplatin to 5-
FU in patients with stage II disease, but a trend towards improved DFS was noted.Howev‐
er, no OS benefit is probably very low in absolute terms (<2%) and difficult to justify given
the excellent overall performance (> 80% at 5 years of operation) and the risk of neurotox‐
icity.  Analysis of a phase III  trial  comparing capecitabine plus oxaliplatin (XELOX) with
bolus 5-FU/LV as adjuvant treatment for colon cancer stage III showed that XELOX was an
improvement of 3 years compared to 5-FU/LV DFS rate [40, 41]. Patients receiving XELOX
had  less  adverse  reactions  such  as  diarrhea,  alopecia,  and  more  neurosensory  toxicity,
vomiting and hand-foot syndrome than patients receiving FU / LV. All these studies suggest
that  FOLFOX,  XELOX  FLOX  and  can  be  used  interchangeably  in  contexts  adjuvant.
Irinotecan is a semisynthetic analogue of camptothecin, originally isolated from the China /
Tibet  ornamental  tree  Camptotheca  acuminata.It  is  a  chemotherapy  agent  that  causes
destruction of cells in S phase-specific topoisomerase I poison in the cell [42]. CALGB 89803
trial by Saltz and colleagues randomized 1264 patients to receive standard weekly bolus 5-
FU / LV bolus regimen or weekly irinotecan and 5-FU bolus / LV. The primary endpoints
of the study were overall survival and disease-free survival. Surprisingly, they found no
difference in either DFS (0.84] or OS (P = 0.74] between the two treatment arms with lethal
and non-lethal toxicity increased by the addition of irinotecan to standard 5FU / LV pattern
43.This trial showed the need for randomized controlled trials adjuvant because advances
in  the  treatment  of  metastatic  disease  does  not  necessarily  translate  into  advances  in
adjuvant  therapy.  Phase  III  trial  was  conducted by large  investigators  PETACC-3.  They
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investigated  whether  the  addition  of  irinotecan  to  LV5FU2 would  improve  disease-free
survival in patients with colon cancer. After surgery, patients with stage II and III colon
cancer were randomized to receive surgery LV5FU2 (LV 200 mg / m 2 infused over 2 hours,
followed by 5-FU as a 400 mg / m 2 bolus and then one of 600 mg / m 2 by continuous
infusion  over  22  hours  on  days  1  and  2  every  2  weeks  for  12  cycles)  with  or  without
irinotecan (180 mg / m 2 infused over 30 to 90 minutes, day 1, every 2 weeks) [44]. After
a median follow-up of  66.3 months,  the rate at  5  years was 56.7% with DFS irinotecan/
LV5FU2  and  54.3%  for  LV5FU2  alone  (p  =  0.106).  They  observed  that  the  addition  of
irinotecan to LV5FU2 was associated with an increased incidence of adverse reactions and
neutropenia. They concluded that irinotecan added to LV5FU2 as adjuvant therapy does
not confer a statistically significant improvement in overall survival or DFS in patients with
colon cancer stage III versus LV5FU2 alone. For the moment, there are no data support‐
ing the use of irinotecan-containing regimens in adjuvant stage II and III patients. Analy‐
sis PETACC-3 trial could not confirm the expected benefit of adding irinotecan in MSI-H
patients. Bevacizumab is a recombinant humanized monoclonal antibody directed against
the vascular endothelial growth factor (VEGF) which is used to inhibit the function of VEGF
in vascular endothelial cells and thereby inhibit tumor angiogenesis-dependent solid tumors
for  growth  and  metastasis  [45].  Bevacizumab  has  demonstrated  clinical  activity  to  in‐
crease in the standard CT metastatic settings.This led to the consideration of this agent in
the adjuvant chemotherapy in the NSABP C-08 trial. More than 2500 patients, most of whom
had stage  III  were  randomized to  receive  FOLFOX6 modified  6  months,  alone  or  with
bevacizumab [46]. In the bevacizumab arm, bevacizumab was administered for more than
6 months, for a total of 1 year of bevacizumab.The primary endpoint of the study was 3
years DFS. The relative risk of FOLFOX plus bevacizumab versus FOLFOX alone was 0.89
(95% CI, 0.76 to 1.04, p = 0.15). This study did not demonstrate the benefits of the use of
bevacizumab in the adjuvant treatment of stage II and III CRC and for this reason the use
of bevacizumab cannot be recommended for use in the adjuvant treatment of patients with
colon cancer.  Cetuximab is a monoclonal antibody capable of inhibiting the degradation
and transmembrane receptor EGFR epidermal growth factor  47.Inhibition of  EGFR is  of
major importance because EGFR control many important activities of tumor cells, includ‐
ing tumor growth and neo - angiogenesis, inhibition of the apoptotic response to chemother‐
apy and radiotherapy.  In a Phase III,  randomized, Alberts  and colleagues evaluated the
potential benefit of cetuximab added to the sixth amended plan FOLFOX.Ils randomized
over  2500  patients  to  receive  12  cycles  of  FOLFOX  every  two  weeks  with  or  without
cetuximab. The mutational status of the KRAS gene was decided at the central level. The
median follow-up of 28 months. Three-year disease-free survival for FOLFOX alone was
74.6% against 71.5% with the addition of cetuximab (HR, 1.21, 95% CI, 0.98 to 1.49, P = 0
08) in patients with wild-type KRAS, and 67.1% against 65.0% (HR 1.12, 95% CI, 0.86 to
1.46, p = 0.38) in patients with mutated KRAS 48.The trial did not demonstrate any benefit
when adding cetuximab to FOLFOX regimen. More patients with grade 3 or higher adverse
events (72.5% versus 52.3%, odds ratio (OR) 2.4, 95% CI, 2.1 to 2.8, p <.001) and failure to
carry Good 12 cycles (33% versus 23%, OR 1.6, 95% CI, 1.4 to 1.9, p <0, 001) were significant‐
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ly higher with cetuximab.Increased toxicity was observed in patients aged 70 years or older.
Therefore, the role of cetuximab in the adjuvant treatment is insignificant for the moment.
6. Chemotherapy in elderly
Colon cancer usually occurs in the elderly with a median age at diagnosis> 70 years in the USA.
Given the increasing life expectancy, patients aged >75 years will be an important component
of oncology practice in the future. Despite this fact, very few patients >75 years participate in
clinical trials. There is disagreement in the administration of standard adjuvant therapy
between young and elderly patients, despite a significant survival benefit for most patients
[49]. The pooled analyzes of safety and efficacy of adjuvant chemotherapy in the elderly
showed comparable rates of toxicity and similar survival benefits compared to younger
patients [50].The majority of data for adjuvant therapy in elderly patients is not the incorpo‐
ration of new therapeutic agents such as oxaliplatin. Subsequent population-based studies
have suggested that older people (eg the elderly category <75 years versus> 75 years [51] were
less likely to have received adjuvant therapy, but experienced similar survival rates compared
younger patients [52]. Finally, although the majority of recommendations to reduce colorectal
cancer screening for persons aged <75 years, the study results indicate that [53] patients aged
>75 years account for almost 20% of cases of colon cancer lymph nodes.In this large population-
based study, investigators found that age was associated with significantly lower rates of
adjuvant chemotherapy administration, whereas the survival benefits of such treatment are
comparable to those of younger patients with stage III in [53] colon cancer.Although chrono‐
logical age alone should not be an exclusion criterion, more work is needed to establish an
optimal strategy and effective way to understand who would benefit most from adjuvant
therapy after surgical resection.
7. Efectivness
Patients with metastatic CRC being treated with chemotherapy are followed closely to monitor
efficacy. There are standardized efficacy measures, such as the RECIST (response evaluation
criteria in solid tumors) criteria, used as endpoints for large clinical trials. A partial response
is defined as a 30% decrease in the longest dimension of each measurable tumor deposit, using
unidimentional, or RECIST criteria [54-56]. A complete response is complete disappearance of
all clinically detectable disease. The response rate (RR) is the percentage of patients who meet
either a partial or complete response. Measures used to determine the duration of treatment
benefit include:
1. progression-free survival (PFS), which is the time from the start of treatment to the date
the disease, worsens;
2. disease-free survival (DFS), which is the length of time patients are free of disease after
completion of curative treatment; and
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3. overall survival (OS), which is the length of time patients are alive after diagnosis or
initiation of treatment for metastatic disease.
8. Postoperative management
Postoperative, or “adjuvant” systemic therapy has become standard for stage III colon cancer.
Adjuvant therapy should also be strongly considered in stage II patients. It is generally
recommended for any medically fit patient with stage II cancer with unfavorable factors,
including colonic perforation, poorly differentiated histology, colonic obstruction, lympho
vascular invasion, or inadequately sampled lymph nodes [61]. The optimal choice of adjuvant
chemotherapy has recently changed from a 6-month course of 5FU-based chemotherapy alone
to a 6-month course of infusional 5FU plus LV and oxaliplatin (FOLFOX) based on a large trial
of adjuvant systemic therapy for resected stage II or III colon cancer [62].This trial demon‐
strated an increase in disease-free survival at 3 years from 72.9 to 78.2% (p = 0.002) with addition
of oxaliplatin to FU/LV. Five-year disease-free survival remained significant (HR: 0.80; p =
0.003) and at 6 years there was an overall survival benefit for stage III patients (68.3% versus
72.9%) [64].Toxicities were comparable between the two groups, with the exception that
oxaliplatin is associated with a much higher rate of paresthesia: 12.4% versus 0.2% grade 3
(serious) toxicity. This neurotoxicity persisted at a grade 3 level in 1.1% of treated patients at
one-year of follow-up.
Many advances have occurred recently in the treatment of metastatic CRC. Active agents, in
addition to the original 5FU, that have been approved by the Food & Drug Administration
(FDA) for mCRC include irinotecan, capecitabine, oxaliplatin, bevacizumab, cetuximab, and
panitumumab. The goals of systemic therapy of mCRC include palliation of symptoms,
prolongation of life, and in selected cases of liver-only metastases, tumor regression to facilitate
surgical resection of these metastases. The median survival of a patient with mCRC has
improved during the last decade from less than 1 year, with only 5FU-based therapy, to ~2
years, with multiagent systemic therapy.
5FU, often modified by LV, has been clinically used for half a century as a standard agent for
mCRC [64]. This was the only available agent until 1996, when irinotecan was approved. Over
the last decade, chemotherapies such as oxaliplatin and capecitabine and targeted agents such
as bevacizumab, cetuximab, and panitumumab have been approved. 5FU blocks the enzyme
thymidylate synthase (TS), which is essential for DNA synthesis. Leucovorin (LV), also known
as folinic acid, enhances the antineoplastic effects of 5FU. Both LV (FOL = folinic acid) and 5FU
(F = fluorouracil) can be combined with irinotecan (IRI) or oxaliplatin (OX) with the treatment
acronyms FOLFIRI or FOLFOX, respectively. These alternative treatments consist of admin‐
istration of a bolus of 5FU, LV, and either oxaliplatin or irinotecan. The patient is then sent
home with a 2-day infusion of low-dose 5FU, administered by a small, lightweight, portable
pump, usually worn on a belt or shoulder strap, infused through a centrally placed catheter.
The patient or health care provider can simply disconnect the catheter after the 2-day infusion.
Capecitabine is an oral fluoropyrimidine with a similar mechanism of action and similar
efficacy as 5FU.
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Irinotecan is a derivative of camptothecin, found in Camptotheca acuminata, a plant native to
China. It potently inhibits topoisomerase I, an enzyme that facilitates the uncoiling and
recoiling of DNA during replication by cleaving one strand and subsequently reattaching that
strand. Oxaliplatin is a platinum chemotherapy that inhibits DNA replication and transcrip‐
tion by forming inter- and intrastrand DNA adducts/cross-links.
In patients with mCRC, optimal chemotherapy consists of initial administration of a fluoro‐
pyrimidine and oxaliplatin or irinotecan (e.g., FOLFOX or FOLFIRI). Tournigand et al [65] and
Colucci et al [66] performed randomized trials where patients received either FOLFIRI
followed by FOLFOX, or vice versa. In the Tournigand et al study, FOLIRI was found to have
a response rate (RR) of 56% and a 8.5-month median progression free survival (mPFS), whereas
FOLFOX had a RR of 54% and a mPFS of 8 months. Colucci et al found that FOLFIRI had a RR
of 31% and FOLFOX had a RR of 34%. Both regimens had a mPFS of 7 months. Both investi‐
gators concluded that both regimens had similar efficacy when used as first-line therapy.
Therefore, either FOLFOX or FOLFIRI can be considered standard options for first-line
treatment of mCRC. These regimens are typically given with bevacizumab.
Bevacizumab is a monoclonal antibody that binds to vascular endothelial growth factor
(VEGF) ligand to inhibit angiogenesis. Its antineoplastic effect is ascribed to regression of
microvascular density, inhibition of neovascularization, and “normalization” of grossly
abnormal tumor vasculature that permits more effective chemotherapy delivery to the tumor.
The FDA recently approved bevacizumab in combination with 5FU-based chemotherapy for
mCRC based on findings that addition of bevacizumab to irinotecan, 5FU, and LV for mCRC
improved PFS from 6.2 months to 10.6 months, improved the response rate from 35 to 45 [67]
and improved overall survival from 15.6 to 20.3 months. Saltz et al found that the addition of
bevacizumab to oxaliplatin-based chemotherapy significantly improved PFS from 8.0 to 9.3
months without an improvement in response rate [68]. The finding of improved PFS without
improved RR is common in trials of targeted therapy because the metastatic lesions can cavitate
or has necrosis rather than regress. Recently, XELOX chemotherapy with or without bevacu‐
zimab was found to be noninferior to FOLFOX with or without bevacuzimab [69]. XELOX
chemotherapy includes a combination of oral 5FU known as capecitabine or xeloda (XEL) plus
oxaliplatin (OX). XELOX can be used as an alternative in patients who cannot tolerate FOLFOX
side effects.
In 2004, the FDA approved cetuximab, the chimeric (human/mouse) monoclonal antibody
targeting epidermal growth factor receptor (EGFR), for treatment of mCRC with irinotecan,
and as a single agent for patients intolerant of irinotecan-based therapy. Early randomized
trials showed benefit of cetuximab in previously treated mCRC patients. When cetuximab was
combined with irinotecan in patients refractory to irinotecan-based chemotherapy, the
response rate was 22.9% versus 10.8% for irinotecan alone [70]. Among patients who failed
previous lines of treatment, monotherapy with cetuximab was found to improve overall
survival, PFS, and quality of life compared with best support care alone [71]. Cetuximab causes
an acneform rash on the face and upper body in more than 80% of patients. The rash is
associated with improved survival.
Colorectal Cancer - Surgery, Diagnostics and Treatment316
Although the FDA approved cetuximab for use in epidermal growth factor receptor (EGFR)
expressing mCRC, there is no evidence that the presence or absence of EGFR expression
influences RR, and routine testing for this is unnecessary. K-ras mutations have been shown
to predict response to cetuximab. The K-ras gene encodes a GTPase protein that is involved in
cell signal transduction pathways [72]. Wild-type (nonmutated) K-ras is found in normal cells.
Approximately 40% of colorectal tumor cells have a mutated K-ras gene resulting in constitu‐
tively active protein and abnormal cell growth, proliferation, and differentiation. Evidence
suggests there is no benefit in using cetuximab monotherapy in previously treated and
untreated mCRC patients who have mutated K-ras tumors. Previously treated metastatic
colorectal patients with mutated K-ras tumors did not benefit from cetuximab monotherapy,
in contrast to patients with wild-type K-ras who had significantly improved overall survival
and PFS [74]. FOLIFIRI and cetuximab as first-line therapy in mCRC was found to reduce the
risk of disease progression; however, the benefit was limited to patients with K-ras wild-type
tumors (HR 0.68, CI 0.50–0.94) [73].
In 2006, the FDA approved panitumumab, a monoclonal antibody to EGFR, which unlike
cetuximab, is fully humanized (not chimeric). It is indicated for patients with mCRC who have
progressed on or are following 5FU, oxaliplatin, and irinotecan-containing regimens. In a large
randomized trial of panitumumab versus best supportive care for mCRC, a response rate of
10% was found [74]. Like cetuximab, panitumumab causes an acneform skin rash. As a fully
human monoclonal antibody, panitumumab has a lower risk of serious infusion reactions than
the 3% rate observed with cetuximab. Similar to cetuximab, panitumumab monotherapy is
more efficacious in patients with wild- rather than mutant-type K-ras tumors. In a randomized
clinical trial of previously treated mCRC patients, median PFS and OS was significantly
improved in the wild-type K-ras group compared with the mutant group [75]. 17% of patients
with wild-type K-ras responded to treatment versus 0% of patients with mutant K-ras. The
relative activity of cetuximab versus panitumumab, as well as the relative activity of panitu‐
mumab when given with chemotherapy, is currently unknown.
9. Rectal cancer
Given the higher local recurrence rates and poorer overall survival of patients with rectal
cancer, multimodality management is important. In the early 1990s, the standard of care
following surgical resection for full thickness (T3–4) or lymph node positive rectal cancer
was postoperative chemoradiotherapy as it was found to improve both local control and
OS compared with surgery alone [77, 78].  Recently, preoperative chemoradiotherapy has
become the treatment of choice for full  thickness rectal  cancers prior to total  mesorectal
excision based on a randomized clinical trial conducted by Sauer et al. Although this trial
showed no difference in OS, improved local recurrence rates (6% versus 13%) were found
for  patients  receiving  preoperative  5FU-based  chemoradiotherapy  as  compared  with
postoperative chemoradiotherapy [79]. Preoperative 5FU chemoradiotherapy as compared
with preoperative radiation alone also has been shown to improve local recurrence rates
(2.7% versus 14.6%) [80].
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10. Liver metastases
The standard of care for patients with resectable liver metastases as their only site of cancer
spread is changing from previous surgical resection alone to a combination of perioperative
chemotherapy and surgery based on a trial conducted by Nordlinger et al [76]. This trial
randomized patients with one to four potentially resectable liver metastases to either perio‐
perative chemotherapy (six cycles of FOLFOX chemotherapy both pre- and postresection) or
surgery alone. The authors concluded that perioperative chemotherapy reduced the risk of
events such as progressive or recurrent disease and death by 25% in eligible and resected
patients without increased severe, life-threatening toxicity. The results of this trial are contro‐
versial because when all randomized patients were included in the analysis only a trend and
not significance in PFS favoring the chemotherapy arm was found.
11. Targeted therapy
Although new drug development takes years, targeted drug use can occur more quickly with
advanced tests and will be a focus of future work. In addition, efforts will focus on identifying
biomarkers that predict response to systemic therapy so that tailored therapy can be initiated.
With  regards  to  the  future  of  adjuvant  systemic  chemotherapy,  microsatellite-instability
(MSI)  testing  of  tumor  DNA may be  used  to  identify  which  patients  will  benefit  from
additional therapy (i.e., predictive biomarker) [81, 82]. Approximately 15% of colon cancers
exhibit MSI commonly caused by loss of DNA mismatch-repair pathways. Tumors display
short repeated nucleotide sequences called microsatellites secondary to frame-shift muta‐
tions  and base-pair  substitutions.  Recent  retrospective  evidence demonstrated that  adju‐
vant  5FU-based  chemotherapy  improved  OS  among  patients  with  microsatellite-stable
tumors. However, there was no benefit to those patients with high MSI [83-90]. Ongoing
trials are attempting to replicate these findings in a prospective manner. The clinical benefit
of  cetuximab,  a  monoclonal  antibody against  EGFR,  varies  greatly  depending on tumor
biology:  the  greatest  benefit  is  among  patients  with  wild-type  (nonmutated)  K-ras  tu‐
mors.  In the metastatic setting,  potential  predictive biomarkers of interest  include K-ras,
epiregulin, B-raf, PTEN, and Pi3K. Jonker et al found that mCRC patients with both high
epiregulin (ligand for EGFR) gene expression and K-ras wild-type status had greater benefit
from cetuximab therapy (HR for overall survival 0.43, p = 0.001) [94]. In addition, loss of
the  tumor-suppressor  gene  PTEN  [95]  and  having  mutated  protein  kinase  B-raf  may
[96]predict for resistance to EGFR therapy such as cetuximab.
12. Discussion
Over the past decade, the prevention and treatment of colorectal cancer has rapidly evolved.
To implement evidence-based care a multidisciplinary team is required including surgeons,
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radiation and medical oncologists, as well as gastroenterologists, radiologists, pathologists,
and primary care physicians. Unfortunately, despite improvements in surgical techniques and
systemic therapy CRC still remains the number two cause of cancer mortality in North
America. This study evaluated the usefulness of oncology assess the standardization of CRC
chemotherapy and the results at the rate of recurrence and survival. The methodology has
enabled the understanding of patterns used for CRC chemotherapy around the world. The
results showed significant differences in patterns between countries, regions and institutions.
In addition, the actual use of CRC chemotherapy may depend on the health policies of the
respective governments. Schemes used are in line with the recommendations of the new
guidelines, with the exception of hospital characteristics depended specialization. In first-line
chemotherapy for stage IV CRC, general hospitals still favored the use of oral fluoropyrimi‐
dines, such as UFT / LV and S-1. However, the differences between general hospitals, cancer
centers and university hospitals has decreased after the revision of the guidelines. In adjuvant
chemotherapy for stage III CRC, cancer centers and general hospitals used similar patterns,
but those that are used in different hospitals. Measures and indicators are greatly needed to
evaluate and improve the quality of cancer treatment. Using market research to develop
indicators for the standardization of care against cancer is a new methodology. Data not only
showed evidence practice gap, but also the growing standardization of CRC affected by
chemotherapy treatment guidelines. Methodology indicates a lack of standardization in the
care of CRC. Oncology market research also has the potential for cost-effectiveness analyzes,
such as sales data for each agent can be evaluated using the analysis system of oncology. Efforts
to improve screening utilization by the general population are required to improve mortality
and morbidity from CRC. Research advances in medical oncology will result in better
understanding of tumor genetics and biology of the host. This will allow systemic therapy to
be tailored to specific tumor molecular targets, while sparing toxicity to normal tissue. With
these improvements in CRC care, the disease will be treatable with tailored medical treatments
that are effective with low toxicity.
13. Recommendations
13.1. Stage II colorectal cancer
• The routine use of adjuvant chemotherapy for all patients with stage II colon cancer is not
recommended. However, the subset of patients with high-risk stage II disease who should
be considered for adjuvant therapy includes patients with inadequately sampled nodes, T4
lesions, perforation, or poorly differentiated histology.
• The ultimate clinical decision should be based on discussions with the patient about the
nature of the evidence supporting treatment, the anticipated morbidity of treatment, the
presence of high-risk prognostic features on individual prognosis, and patient preferences.
• When treated with adjuvant therapy, high-risk stage II patients should receive similar
regimens to those recommended for stage III patients. The enrolment of resected high-risk
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stage II patients in clinical trials is encouraged. Additional trials comparing adjuvant
therapy with observation are needed and are ethically acceptable in stage II colon cancer.
13.2. Stage III colorectal cancer
It could be recommended that patients with completely resected stage III colon cancer should
be offered adjuvant chemotherapy and that this treatment should start within eight weeks of
surgery. Treatment should depend on factors such as patient suitability and preference, and
patients and clinicians must work together to determine the optimal course of treatment. The
recommended treatment option is:
• 5-FU given intravenously in combination with leucovorin (LV) and oxaliplatin in the
regimens known as FOLFOX or FLOX. These 5-FU/LV/oxaliplatin regimens have demon‐
strated superior DFS when compared with 5-FU plus LV and are the recommended
regimens. Oxaliplatin administration is associated with a 1% risk of persistent grade 3
neuropathy that needs to be considered in conjunction with expected benefits of therapy.
• Some patients would not be considered appropriate for oxaliplatin regimens. Examples
include patients with underlying neurologic conditions or at increased risk of neuropathy,
patients at increased risk for infections, and patients likely to poorly tolerate infections as a
result of chemotherapy. For these patients, the treatment options are:
• Oral capecitabine administered for six months, which has equivalent efficacy to intravenous
5-FU/LV. Capecitabine results in significantly less diarrhea, stomatitis, neutropenia, nausea/
vomiting, and alopecia but significantly more hand-foot syndrome when compared with 5-
FU/LV.
• 5-FU in combination with LV administered for six months using either the weekly or
monthly schedule.
Suitable patients should be offered entry into clinical trials testing new adjuvant treatments
for resected stage III colon cancer.
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